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Abstract
Aims/hypothesis Diabetes is associated with an increased risk of dementia. We estimated the potential impact of trends in
diabetes prevalence upon mortality and the future burden of dementia and disability in England and Wales.
Methods We used a probabilistic multi-state, open cohort Markov model to integrate observed trends in diabetes, cardiovascular
disease and dementia to forecast the occurrence of disability and dementia up to the year 2060. Model input data were taken from
the English Longitudinal Study of Ageing, Office for National Statistics vital data and published effect estimates for health-state
transition probabilities. The baseline scenario corresponded to recent trends in obesity: a 26% increase in the number of people
with diabetes by 2060. This scenario was evaluated against three alternative projected trends in diabetes: increases of 49%, 20%
and 7%.
Results Our results suggest that changes in the trend in diabetes prevalence will lead to changes in mortality and incidence of
dementia and disability, which will become visible after 10–15 years. If the relative prevalence of diabetes increases 49% by
2060, expected additional deaths would be approximately 255,000 (95% uncertainty interval [UI] 236,000–272,200), with
85,900 (71,500–101,600) cumulative additional cases of dementia and 104,900 (85,900–125,400) additional cases of disability.
With a smaller relative increase in diabetes prevalence (7% increase by 2060), we estimated 222,200 (205,700–237,300) fewer
deaths, and 77,000 (64,300–90,800) and 93,300 (76,700–111,400) fewer additional cases of dementia and disability, respectively,
than the baseline case of a 26% increase in diabetes.
Conclusions/interpretation Reducing the burden of diabetes could result in substantial reductions in the incidence of dementia
and disability over the medium to long term.
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Abbreviations
CVD Cardiovascular disease
DPM Diabetes Prevalence Model
ELSA English Longitudinal Study of Ageing
IMPACT-BAM IMPACT Better Ageing Model
LYG Life years gained
PAR Population attributable risk
PARF Population attributable risk fraction
PHE Public Health England
UI Uncertainty interval
Introduction
The rapid ageing of populations in high-income countries has
triggered major concerns regarding the future burden of age-
related chronic diseases. In England and Wales, there are
around 800,000 people living with dementia, and this number
is set to increase by 60% by 2040 [1]. A substantial increase is
also predicted for the number of people living with any func-
tional impairment (disability). This constitutes a major policy
challenge [2].
Currently, there is no dementia treatment that can signifi-
cantly modify disease progression. However, several modifi-
able risk factors for dementia and disability have been identi-
fied, thus creating the possibility for prevention. Up to 35% of
cases of dementia are attributable to a combination of nine risk
factors: low educational attainment, midlife hypertension,
midlife obesity, hearing loss, late-life depression, diabetes,
physical inactivity, smoking and social isolation [3].
Reducing these risk factors can have a substantial impact on
the risk of developing dementia. During 25 years of follow-up in
a large cohort study in the USA, dementia incidence was approx-
imately 80% higher in those with diabetes compared with those
without diabetes [4]. Among individuals in late midlife, those
with diabetes had a 24% faster cognitive decline than those with-
out diabetes [5]. For disability, the Global Burden of Disease
Study showed that diabetes was the sixth most common cause
of disability in 2015 [2]. England andWales have recently expe-
rienced favourable declines in smoking prevalence and BP
levels. These possibly explain the 2.7% annual decrease in
dementia incidence observed in the last two decades [1].
However, there is evidence of worsening trends in other, poten-
tially important, risk factors for both dementia and disability. The
prevalence of adult obesity increased from 15% in 1993 to 26%
in 2010 before recently plateauing [6]. Type 2 diabetes preva-
lence, driven mainly by obesity trends, more than doubled
between 1993 and 2015 and is expected to increase further from
8.6% in 2015 to 9.7% by 2035, generating more than 1.1 million
additional cases in England [7, 8]. Midlife obesity and type 2
diabetes have both been shown to be related to dementia and
disability incidence, based on evidence from observational stud-
ies [2, 9, 10].
The UK government has responded with prevention efforts
to reduce the burden of obesity and diabetes. These include
the Diabetes Prevention Programme which targets individuals
at highest risk. There have also been population-based policy
approaches to prevent obesity such as the soft drinks industry
levy, sugar and ‘calorie’ reduction programmes, and national
marketing campaigns [11, 12]. Despite these efforts, future
trends in obesity and diabetes prevalence remain uncertain.
Research in context
What is already known about this subject?
 Diabetes increases the risk of developing dementia and disability
 The prevalence of type 2 diabetes has increased globally, alongside the increasing epidemic of obesity
 There are complex inter-relationships between the projected ageing population in England and decreasing 
incidence of cardiovascular disease and dementia, which are not accounted for in existing studies
What is the key question?
 What is the potential impact of trends in diabetes prevalence upon mortality and future burden of dementia and 
disability in England and Wales?
What are the new findings?
 Reducing the burden of diabetes could result in considerable reductions in incidence of dementia and disability
 This impact could be substantial, but would not be felt fully for some decades
How might this impact on clinical practice in the foreseeable future?
 Public health interventions aimed at decreasing the incidence of diabetes may contribute to decreasing the future 
incidence of dementia and disability, but only after a time lag measured in decades
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Correspondingly, the burdens of dementia and disability,
including mortality rates, are unknown.
In this study, we aimed to estimate the potential effects of
future trends in diabetes prevalence on mortality outcomes
and the future burden of dementia and disability in England
and Wales up to 2060.
Methods
We conducted our analyses in two stages: first, we estimated
plausible future trends in diabetes prevalence given different
futures for the obesity trends using the Diabetes Prevalence
Model (DPM) developed by Public Health England (PHE).
Second, we estimated future trends in diabetes prevalence
and examined their potential effects upon dementia and
disability over the period 2015–2060 in the England and
Wales population using our previously validated IMPACT
Better Ageing Model (IMPACT-BAM) [1, 13]. The flowchart
in Fig. 1 describes how these two steps are connected.
Future diabetes trends
In the first step, we examined four plausible future diabetes
prevalence scenarios based on obesity prevalence projections.
We assumed different futures for the currently increasing
obesity trends—no change, a further acceleration, a halt, and
finally, a reverse—and translated these into expected future
trends in diabetes prevalence using the DPM [7]. We used this
model to estimate possible future trends in diabetes prevalence
given the four different futures for the currently increasing
obesity trends, ranging from a 5 yearly change in the obesity
prevalence of −3 to +5%. Each one of the projected trends in
diabetes prevalence from 2015–2060 was used as a different
scenario to be explored later in IMPACT-BAM (see electronic
supplementary material [ESM] Chapter 4.4 and ESM Fig. 12).
The baseline scenario assumed a continuation of recent
trends in leading diabetes drivers, mainly an increase in obesi-
ty prevalence of 1% every 5 years. This obesity trend corre-
sponds roughly to the last 5 years of change in obesity report-
ed in the Health Survey for England study [8]. For this trend,
the DPM predicted a 26% rise in diabetes prevalence from
8.6% in 2015 to 10.8% in 2060.
Three additional scenarios, based on current trends in
drivers of diabetes (a further acceleration, a halt, and a reverse
in the current obesity trend) were evaluated against the base-
line scenario. These scenarios were: (A) an increase in relative
diabetes prevalence of 49%; (B) an increase by 20%; and (C) a
slowing down of the increase to 7% by 2060. Details of all
modelled scenarios are presented in Table 1 and ESM
Chapter 4.4.
Effect of diabetes trends in dementia and disability
Overview of the IMPACT-BAM model We extended the
IMPACT-BAM to estimate the potential effects of the plausi-
ble changing trends in diabetes prevalence upon dementia and
disability over the period 2015–2060 in the England and
Wales population.
Diabetes 
prevalence model
IMPACT-BAM
Future trends in obesity 
prevalence
CVD and Non-CVD 
mortality trends
CVD, demena and 
disability incidence and 
prevalence
Populaon esmates and 
projecons
Future trends in diabetes 
prevalence
Future demena and 
disability incidence and 
prevalence trends 
(and trends for other 
condions) 
Life years
Input data ModelOutput data
Fig. 1 Diagram illustrating steps of the analysis
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IMPACT-BAM is a probabilistic multi-state, open cohort
Markov model which follows the progression of a healthy popu-
lation (aged ≥35 years) of England andWales from 2006 to 2060
into eight different health states characterised by the presence or
absence of cardiovascular disease (CVD), cognitive impairment,
dementia and moderate to severe disability, and two states for
death from CVD and non-CVD causes (ESM Fig. 1).
Before running the simulation, we populated each state in the
model based on the Office for National Statistics population
estimates in 2006 (start year) and prevalence of the above condi-
tions from the English Longitudinal Study of Ageing (ELSA),
except for the new cohort of 35-year-olds that enters the system
through the disease-free state. The simulation allows individuals
to move to other states in the model. The arrows in ESM Fig. 1
indicate the possible movements of people between these ten
states, which are governed by one-year probabilities of transition.
For example, a healthy 55-year-old man starts the simulation in
state 1 (disease-free state) in 2006. He moves to state 2 (CVD) in
2007 after having a stroke. In 2008 he could either die from
complications of the stroke (he moves to state 9), die from any
other causes (he moves to state 10), or he could develop cogni-
tive impairment (moving to state 3) or disability (moving to state
5). As above, movements to any state are driven by transition
probabilities.
Transition probabilities were previously calculated using
combined data from the ELSA and mortality projections.
These projections were estimated separately for cardiovascu-
lar and non-cardiovascular mortality rates based on observed
data reported by the Office for National Statistics up to 2016.
P-spline smoothed lines [14–16] were fitted to logarithmic
transformed CVD and non-CVD mortality rates in each 5-
year age band from 1990 to 2016 by sex using the p-spline
function in Stata software. Additional details are provided in
the ESM Chapter 2 and ESM Figs 2–5.
We defined disability as the inability to independently carry
out one or more activities of daily living, which included getting
in or out of bed, walking across a room, bathing or showering,
using the toilet, dressing, cutting food and eating. This definition
of disability captures individuals who have difficultymaintaining
independence and require supportive care.
Dementia was defined on the basis of the coexistence of
cognitive impairment and disability, or a report of a doctor
diagnosis of dementia by the participant or caregiver.
Cognitive impairment was defined as an impairment in two
or more functional tests (such as orientation to time, immedi-
ate and delayed memory, verbal fluency and numeracy func-
tion) or a score higher than 3.6 on the Informant Questionnaire
on Cognitive Decline (IQCODE) [17].
A more detailed overview of the model can be found in the
previously published papers [1, 13] and ESM Chapters 1–2
and ESM Figs 1–5. Information about model validation is
provided in ESM Chapter 3 and Figs 6–9. A general descrip-
tion of these types of Markov models can be found in the
paper by Briggs and Sculpher [18].
Diabetes trends effect on transition probabilities For this
study, we assumed that trends in the prevalence of type 2
diabetes from each scenario, calculated in the first stage,
would modify some of the IMPACT-BAM transition proba-
bilities, which ultimately would result in changes in the
burden of dementia and disability. We assumed that the affect-
ed transition probabilities were those representing the risk of
CVD and non-CVD death, cognitive decline incidence, CVD
incidence, disability incidence and recovery from disability.
To model these changes in transition probabilities, we used an
approach based on the population attributable risk fraction
(PARF). The PARF calculates the proportion bywhich disease
burden would be reduced if there were no diabetes in the
population. A simpler version of this approach has been used
previously in other IMPACT models [19, 20].
Previous research has demonstrated that the association
between diabetes and cognitive decline and CHD is dependent
upon diabetes duration [21]. This is consistent with the view
that the presence of vascular risk factors and insulin resistance
in midlife increase the risk not only of developing diabetes
and atherosclerosis but also of cognitive decline and dementia
later in life. The development of hyperglycaemia, glucose
intolerance, microvascular and macrovascular complications
that are associated with type 2 diabetes then further accelerate
diabetes-associated cognitive decline.
Table 1 Predicted prevalence of
type 2 diabetes by calendar year
for four scenarios of trends in
obesity, compared with the base-
line scenario
Scenario Change in obesity
prevalence
(%/5 years)
Change in diabetes
prevalence by 2060
(%)
Calendar year
2015 2020 2030 2040 2050 2060
Diabetes prevalence (%)
A +5 +49 8.6 9.1 10.1 11.1 12.0 12.8
Baselinea +1 +26 8.6 9.0 9.6 10.1 10.5 10.8
B 0 +20 8.6 8.9 9.5 9.9 10.2 10.3
C −3 +7 8.6 8.8 9.1 9.3 9.3 9.2
Projection of diabetes prevalence based on estimates from PHE DPM using different assumptions of future
obesity trends [7]
a Baseline scenario is that the current trend in the prevalence of obesity will continue
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To account for the effect of diabetes duration, we used the
extended formula of PARF to account for multi-category expo-
sures [22]. The different categories of exposure represent six
different categories of lengths of time living with the disease:
diabetes duration of fewer than 5 years; 5–9 years; 10–14 years;
15–19 years; 20–24 years and more than 25 years.
The extended PARF formula requires: (1) age- and sex-
specific estimates of the risk factor prevalence at each expo-
sure level; and (2) RRs comparing every exposure level with
the unexposed group (i.e. stratified by age, sex and affected
transition probability). We used the 2014 Health Survey for
England (HSE) data to obtain age- and sex-specific distribu-
tions of diabetes prevalence across the six categories of diabe-
tes duration. For the baseline scenario, we assumed that the
prevalence in each of the categories would remain constant in
the future. For the rest of the scenarios, we modified the prev-
alence in each category across time to match the ageing of the
population (more details are provided in ESM Chapter 4.5
and Figs 13–20) We obtained the RRs from published studies
and by carrying out meta-analyses (see ESM Chapter 4, ESM
Figs 10–11 and ESM Table 1). All RRs used had been adjust-
ed for BMI. Then, we adjusted these RRs by diabetes duration
using the results from the ADVANCE trial, which quantifies
the risk for macro- and microvascular complications and all-
cause death for each 5 year increase in diabetes duration [23].
Ultimately, we were interested in how the PARF changes
because of trends in diabetes prevalence. Symbolically, this
would be:
ΔPARF ¼ PARF − PARF0
where PARF′ is the calculated PARF for the (lower) diabetes
prevalence from the baseline scenario.
Outcomes For each scenario, theΔPARF was then multiplied
by the appropriate transition probability to generate a new
transition probability. We repeated this procedure for all the
transition probabilities. We then recalculated the IMPACT
model with the new set of transition probabilities and gener-
ated scenario-specific numbers of cases of dementia, disability
and deaths from 2016 onwards and compared them against the
baseline scenario (i.e. the model with the original transition
probability values).
Finally, we reported the cumulative number of new cases of
dementia, disability and deaths attributable to each scenario
for the population aged 65 and over, in comparison with the
baseline scenario. We also presented life years gained (LYG)
for each scenario and the proportion of life spent with
disability.
Sensitivity analysis To explore the impact of parameter uncer-
tainty on model outputs, we conducted a probabilistic sensi-
tivity analysis using Monte Carlo simulation. The procedure
entailed iterative sampling from specified distributions for the
input parameters that were used in the model, and then re-
calculation of the outputs. We performed 1000 iterations to
estimate 95% uncertainty intervals (95% UIs) for the output
variables.
The model was developed as a package in R software
(version 3.4.2, https://cran.r-project.org). Detailed
information on preparing scenarios data and methods used to
evaluated the effect of diabetes on model transition
probabilities can be found in ESM Chapters 4–6 and ESM
Figs 10–20.
Results
Baseline scenario
Our IMPACT-BAM baseline results (see Table 2) suggested
that the number of disability incident cases among the popu-
lation aged 65 and over is expected to increase from approx-
imately 223,600 (95% UI 219,200–228,100) per year in 2015
to 288,100 (275,900–300,200) in 2045 and then fall slightly to
271,600 (253,900–287,400) in 2060. The number of incident
dementia cases is also expected to rise from approximately
142,000 (137,000–147,300) per year in 2015 to 208,500
(197,400–218,900) in 2045 and 203,700 (189,100–217,500)
in 2060.
This increase in the number of annual incident cases
occurred despite a continuous decline in the incidence rates
of dementia and disability. This suggests that the reason for
the increasing number of projected new cases of dementia and
disability is the projected ageing of the population, due to
increasing longevity. The incidence of disability expressed
per 1000 population aged ≥65 is forecasted to decrease from
approximately 21.4 (95% UI 21.0–21.9) per 1000 person-
years in 2015 to 17.1 (16.6–17.6) in 2045 and then 13.9
(13.3–14.4) in 2060. This decrease is also observed for
dementia, with an expected fall from 13.6 (13.1–14.1) per
1000 person-years in 2015 to 12.4 (11.8–12.9) in 2045 and
10.4 (9.9–10.9) in 2060.
The projected total mortality rate in people aged ≥65 is
predicted to decrease by approximately 39% between 2015
and 2060, from 38.7 (95% UI 38.3–39.2) to 23.6 (22.7–
25.0) per 1000 population.
Comparison of three future scenarios
Effect of diabetes trends on projected mortality For the most
adverse scenario (A) we might expect about 79,700 (95% UI
72,500–86,000) additional deaths attributable to diabetes by
2045 (43.4 deaths per 100,000 population) and approximately
255,000 (236,000–272,200) additional deaths (79.5 per
100,000) by 2060 (Table 3). This corresponds to
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approximately 650,000 (580,000–700,000) cumulative life
years lost by 2045 and 2,570,000 (2,350,000–2,770,000) by
2060, which is 0.9% of life years lost for 2060 in comparison
with the baseline scenario.
In contrast, for scenario B we might expect about 18,900
(95% UI 17,200–20,400) fewer deaths due to diabetes by
2045 and 58,600 (54,300–62,600) by 2060 in comparison
with the baseline scenario. This resulted in projected LYG of
150,000 (140,000–170,000) and 600,000 (550,000–650,000)
by 2045 and 2060, respectively. This corresponds to a 0.2%
increase in the number of life years in comparison with the
baseline scenario in 2060.
For the most optimistic scenario (C), we might expect
approximately 73,000 (95% UI 66,500–78,800) and 222,200
(205,700–237,300) fewer deaths in comparison with the base-
line scenario, for 2045 and 2060, respectively (Table 3). This
results in gaining approximately 600,000 (540,000–660,000)
additional life years by 2045 and 2,290,000 (2,090,000–
2,470,000) life years by 2060 (Fig. 2), an increase in life years
of 0.8% in comparison with the baseline scenario in 2060.
Effect of diabetes trends on disability and dementia Our
results suggest that any changes in diabetes prevalence will
have almost no effect on dementia and disability burden in the
next 5 years (see Table 4). However, these effects increase
significantly during subsequent decades. For scenario A
(49% increase in diabetes up to 2060), we might expect
approximately 104,900 (95% UI 85,900–125,400) additional
cases of disability and some 85,900 (71,500–101,600) addi-
tional cases of dementia before 2060. On the other hand, if
there is a deceleration in the rate of increase of diabetes prev-
alence (scenario B), we might avoid approximately 24,400
(20,000–29,200) new cases of disability and 20,100
(16,800–23,700) new cases of dementia cumulatively by
2060.
The most optimistic scenario (C) might result in approxi-
mately 93,300 (76,700–111,400) fewer cumulative new cases
of disability and 77,000 (64,300–90,800) fewer cases of
dementia by 2060. This corresponds to 2.2% fewer new cases
of dementia and 1.9% fewer cases of disability in comparison
with the baseline scenario in 2060.
Compression of morbidity The projected trends in diabetes
prevalence appeared to affect the proportion of life years spent
with disability. The percentage of life years in the population
spent with disability was 0.4% lower for scenario C (most
optimistic) than the baseline scenario, and 0.9% lower than
scenario A (most pessimistic) (Fig. 3).
Discussion
Key findings
Our study suggests that a reduction in diabetes prevalence
would result in a decline in age-specific incidence of dementia
and disability and postpone these conditions to later years in
life. However, trends in the incidence of dementia and disabil-
ity at the population level would not be observed for a decade
as a result of decreases in mortality and prolongation of life.
Table 2 Projected number and rate of incident cases of disability, dementia and mortality in the England andWales population aged ≥65 in 2030, 2045
and 2060, compared with those observed in 2015 for the baseline scenario
Sex Year Disability incident cases Dementia incident cases Total deaths
Number (thousands) Per 1000 population Number (thousands) Per 1000 population Number (thousands) Per 1000 population
All 2015 224 (219 to 228) 21.4 (21.0 to 21.9) 142 (137 to 147) 13.6 (13.1 to 14.1) 404 (401 to 408) 38.7 (38.3 to 39.2)
2030 269 (261 to 276) 19.3 (18.8 to 19.8) 187 (179 to 194) 13.4 (12.9 to 13.9) 442 (436 to 449) 31.7 (30.9 to 32.6)
2045 288 (276 to 300) 17.1 (16.6 to 17.6) 209 (197 to 219) 12.4 (11.8 to 12.9) 471 (466 to 478) 27.9 (27.0 to 29.1)
2060 272 (254 to 287) 13.9 (13.3 to 14.4) 204 (189 to 218) 10.4 (9.9 to 10.9) 462 (458 to 468) 23.6 (22.7 to 25.0)
Men 2015 100 (96.1 to 104) 21.2 (20.3 to 22.1) 61 (57 to 66) 13.0 (12.0 to 14.0) 192 (190 to 194) 40.6 (40.0 to 41.1)
2030 126 (120 to 132) 19.4 (18.4 to 20.3) 86 (80 to 92) 13.2 (12.2 to 14.3) 217 (214 to 220) 33.3 (32.5 to 34.3)
2045 137 (128 to 146) 17.1 (16.1 to 18.1) 99 (91 to 107) 12.3 (11.3 to 13.3) 233 (230 to 236) 29.0 (27.9 to 30.2)
2060 132 (120 to 142) 13.8 (12.8 to 14.8) 99 (88 to 109) 10.4 (9.4 to 11.4) 232 (230 to 235) 24.3 (23.4 to 25.7)
Women 2015 123 (121 to 126) 21.6 (21.2 to 22.0) 81 (79 to 83) 14.1 (13.8 to 14.5) 213 (211 to 215) 37.2 (36.8 to 37.7)
2030 143 (139 to 147) 19.2 (18.8 to 19.7) 101 (97 to 104) 13.6 (13.1 to 14.0) 225 (222 to 229) 30.3 (29.5 to 31.2)
2045 151 (145 to 156) 17.1 (16.6 to 17.5) 110 (105 to 114) 12.4 (11.9 to 12.9) 238 (236 to 242) 26.9 (26.1 to 28.1)
2060 140 (132 to 147) 14.0 (13.6 to 14.3) 105 (99 to 110) 10.5 (10.1 to 10.9) 230 (228 to 233) 22.9 (22.1 to 24.3)
The baseline scenario is that the current trend in the prevalence of diabetes will continue, which will result in a 26% increase in diabetes prevalence by
2060
95% UIs are shown in brackets
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Crucially, our study also suggests that substantial reductions
in diabetes prevalence would compress morbidity, decreasing
the percentage of life spent with disability by approximately
0.4% (see Fig. 3).
Our study is the first, to our knowledge, to estimate the
potential effect of future diabetes trends on the future UK
burden of disability and dementia while taking into account
the complex population dynamics of morbidity and mortality.
Barnes and Yaffe [24] estimated the fraction of cases of
Alzheimer’s disease attributable to diabetes by calculating its
population attributable risk (PAR) as 2%worldwide and 3% in
the USA. This corresponds to 81,000 and 17,000 fewer cases
of dementia each year worldwide and in the USA, respective-
ly, if diabetes prevalence decreases by 10%. Our results are far
more conservative. It is likely that Barnes and Yaffe’s analysis
over-estimated the potential burdens, because it did not
account for any observed trends in risk factors, mortality or
dementia, nor consider competing risks of mortality from
CVD as opposed to dementia. Moreover, these analyses,
based on simple PAR approaches, did not account for any
relationship between diabetes duration and outcomes.
Several studies have reported that the RR of fatal CHD
increases in individuals with diabetes as the years lived with
the disease increases [21, 23, 25].
Strengths and limitations
The IMPACT-BAM model accounts for complex epidemio-
logical interactions between several important sources of
morbidity like CVD, dementia and disability, which share
some risk factors. The structure of the model allowed us to
take into account the risks between these conditions and
competing risks of dying from cardiovascular and non-
cardiovascular causes. Diabetes increases the risk of dying,
not only from CVD, but also from many other diseases,
including several cancers. Given the declining population risk
of CVD mortality in future years, the competing risk of non-
CVDs is expected to become critical. Our model accounts for
this by separating projections of future cardiovascular and
non-cardiovascular risk of death, which represents a substan-
tial improvement on previous methodologies [24, 26].
Specifically, we account for trends in CVD- and non-CVD
mortality and incidence, trends in dementia incidence,
competing risks between cardiovascular and non-
cardiovascular risk factors. Our methods also account for the
increase in risk of both CVD and dementia caused by the time
spent living with diabetes. IMPACT-BAM also models the
time lag between newly developed diabetes and its complica-
tions. To our knowledge, there are no previous studies model-
ling the effect of prevention of diabetes on dementia and
disability which also take into consideration the time needed
to develop diabetes complications. This makes our estimates
closer to real-life settings. Finally, our prediction model esti-
mates the positive and negative effects of changes in diabetes
prevalence. Our scenarios of possible future diabetes burden
were based on reasonable assumptions of future obesity
trends.
Our study also has limitations. Our approach does not
account for any effect of change in the obesity distribution
in the population not mediated through diabetes, including
the effect on hypertension prevalence. This means that our
results may be conservative. However, obesity is a less strong
risk factor for dementia than diabetes [4].
We used the pre-existing model published by PHE, the
DPM, to calculate expected trends in diabetes prevalence if
the obesity prevalence increase accelerates (scenario A), stops
(scenario B) or reverses (scenario C). Although obesity is
widely recognised as the main driver of the current diabetes
epidemic, diabetes trends can also be driven by many other
risk factors that may have contrasting trends such as physical
activity or pharmacological intervention in individuals with
impaired glucose tolerance [27]. In addition, the DPM model
(available on PHE official website) lacks information on any
potential methodological limitations. Moreover, our approach
to projecting the future distribution of the diabetes duration in
the population does not account for increased risk of death due
to longer duration of diabetes. This can lead to overestimation
of the number of participants with longer duration of diabetes,
and overestimating the total effect of a change in diabetes
prevalence on dementia and disability incidence.
We used a multi-exposure, PARF approach to translate
trends in diabetes prevalence to changes in the risk of demen-
tia and cognitive impairment. This approach assumes causal-
ity of risk factor and disease. The evidence is still not as strong
as it is for the association between some other risk factors and
Fig. 2 Cumulative number of LYG for modelled scenarios (thousands)
for England and Wales, population aged ≥65. The shading represents
95% UIs. Scenarios: A, 49% increase in diabetes by 2060; B, 20%
increase in diabetes by 2060; C, 7% increase in diabetes by 2060
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diseases. However, there is increasing evidence of the associ-
ation between diabetes and dementia [4, 28–31].
Finally, all the disability caused by conditions other than
dementia and CVD is aggregated into a single model state. As
a consequence, the transition probabilities of moving from this
state to other states are not specific for these conditions, but
rather represent an average probability for all other causes of
disability. Nevertheless, because the ELSA sample is repre-
sentative for the population of England and Wales, the esti-
mated combined probabilities should be generalisable.
Public health implications
Our findings have implications for the medium and long term.
With a 35-year perspective we might expect a shift in the
burden of diabetes consequences, from CVD towards a much
broader range of sequelae including dementia. Our study
suggests that preventing diabetes is important, not only for
future CVD, but also for the dementia and disability burden.
Moreover, as CVDmortality continues to decline, we expect a
further shift in the burden of diabetes to non-cardiovascular
complications. Contrary to some other diabetes complications,
such as nephropathy or retinopathy, people with cognitive
decline and dementia cannot be offered treatment to signifi-
cantly slow down the progress of the disease. Since an older
population structure is the leading reason for the increase in
the dementia burden, it is reasonable to expect that dementia
will increase as a share of diabetes complications.
Constraining the diabetes epidemic could reduce dementia
incidence in future decades, however the effect is likely to be
gradual. The risk of CVD improves almost immediately in
response to interventions that decrease serum cholesterol, BP or
smoking [32]. In contrast, our study suggests a much longer time
lag between decreases in population rates of obesity and diabetes,
and subsequent reductions in the dementia and disability burden.
Evidence suggests that upstream, structural interventions are
far more powerful prevention strategies, and also more likely to
reduce inequalities, than individual level agentic interventions
[33]. Several UK policies now aim to halt the rise in obesity
and diabetes prevalence, including the Calorie Reduction
Programme, the Sugar Reduction Programme, marketing
campaigns, the Soft Drinks Industry Levy and National
Diabetes Prevention Programme [11, 12, 34]. In terms of indi-
vidual level interventions, the English NHS Health Check
programme for adults aged 40–74, which already includes
HbA1c or fasting blood glucose to identify diabetes in people
with high BMI and/or BP, has recently been updated to include
dementia advice. This may be useful for patient education as
recent research suggested nearly half of adults over 50 did not
know that a healthy lifestyle could help prevent dementia [35].
Conclusions
Future reductions in diabetes prevalence could reduce the
burden of disability and dementia, however these reductions
in dementia and disability burden will be observed in the mid
to long term. Other preventative interventions targeting the
shared determinants of these and other non-communicable
diseases must be harnessed to stem the rising tide of dementia
and disability in England.
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Fig. 3 Projected percentage of life years spent with disability in 2060 for
England andWales, population aged ≥65. In the baseline scenario, 24.2%
of life years were spent with disability (horizontal solid line). Bars repre-
sent corresponding proportions for scenarios A, B and C. Error bars
represent 95% UIs. Scenarios: A, 49% increase in diabetes by 2060; B,
20% increase in diabetes by 2060; C, 7% increase in diabetes by 2060
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